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Abstract
Approximately 500,000 individuals diagnosed with bladder cancer in the U.S. require routine cystoscopic follow-up to
monitor for disease recurrences or progression, resulting in over $2 billion in annual expenditures. Identification of new
diagnostic and monitoring strategies are clearly needed, and markers related to DNA methylation alterations hold great
promise due to their stability, objective measurement, and known associations with the disease and with its clinical features.
To identify novel epigenetic markers of aggressive bladder cancer, we utilized a high-throughput DNA methylation bead-
array in two distinct population-based series of incident bladder cancer (n=73 and n=264, respectively). We then validated
the association between methylation of these candidate loci with tumor grade in a third population (n=245) through
bisulfite pyrosequencing of candidate loci. Array based analyses identified 5 loci for further confirmation with bisulfite
pyrosequencing. We identified and confirmed that increased promoter methylation of HOXB2 is significantly and
independently associated with invasive bladder cancer and methylation of HOXB2, KRT13 and FRZB together significantly
predict high-grade non-invasive disease. Methylation of these genes may be useful as clinical markers of the disease and
may point to genes and pathways worthy of additional examination as novel targets for therapeutic treatment.
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Introduction
In the United States in 2009, an estimated 71,000 cancers of the
urinary bladder were diagnosed and greater than 14,000 deaths
were attributed to this disease [1]. The vast majority of deaths
occur in patients with incident high stage, high grade, invasive
tumors that infiltrate the muscular layers of the bladder. Low
grade, non-invasive disease, on the other hand, can be successfully
treated, though this success comes at great economic burden to the
healthcare system. Approximately 500,000 patients require
monitoring in the U.S. leading to estimated diagnosis to death
per patient costs ranging from $96,000 to $187,000, thereby
resulting in $2.2 billion in annual expenditures, making bladder
cancer the most expensive of all cancers [2,3]. Thus, cost-effective
prognostic strategies for evaluating incident and recurrent disease
would be of significant clinical utility.
Epigenetic control of DNA expression is well known to drive
fetal developmental differentiation. In a parallel fashion, in concert
with genetic events (mutation, deletion and gene amplification) it is
thought that epigenetic alterations may precipitate important
pathological features of malignant degeneration [4]. Bladder
cancer, with its divergent clinical (and pathological) phenotypes,
presents a tumor model that may arise by inactivation of loci that
independently control the propensity for invasion and, hence,
dictate stage and grade, and that this inactivation may occur
through a variety of epigenetic processes including microRNA
alterations [5], alterations to chromatin [6,7], and alterations to
DNA methylation [8]. In this case, there is potential for the use of
epigenetic alterations and particularly DNA CpG methylation as
biomarkers for bladder cancers, as well as, potentially, for a variety
of other human cancers [8,9,10,11,12,13,14]. Microarray-based
approaches also have attempted to identify novel genes associated
with invasive disease but with limited sample sizes due to the array
strategy employed [15]. Recent developments in array approaches
now allow for application of these technologies to population-
based epidemiologic studies of cancer utilizing large numbers of
samples [16,17,18]. There are numerous advantages to utilizing a
population-based approach, including reduction in bias, greater
generalizability of the results, and access to samples spanning all
stages and grades of the tumor. Therefore, we have utilized this
array-based approach to identify clinically and biologically
informative patterns and novel gene targets of DNA CpG
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cell carcinoma.
Results
Identification of candidate loci
We utilized a 2-step approach to the identification and
validation of loci that were associated with the development of
invasive bladder cancer (Figure S1). In step 1, two independent
series of tumors (Table 1) were analyzed by DNA methylation
array to identify potential candidate loci having differential
methylation, and in step 2, these candidates were confirmed in
an additional series of tumors not profiled on the array.
Overall, there was a general increase in methylation in invasive
tumors (Figure 1A), suggesting that this approach has utility for
demarcation of effective biomarkers. Generalized linear models
comparing methylation levels of invasive versus non-invasive tumors
at each locus confirmed this visual impression. In series 1, 445 CpG
loci had significantly increased methylation in invasive compared to
non-invasive tumors (Q,0.05) while only 68 loci had significantly
decreased methylation. Similarly, in series 2, 606 loci had significantly
increased methylation and only 41 had significantly decreased
methylation (Table S1). Modeling each series, independently, with
recursively partitioned mixture models yielded four methylation
profiles (Fig 1B). Notably, significantly more invasive tumors were in
methylation class 4 (P,0.00001, permutation chi-square).
To identifythe loci most robustly associated withinvasive disease,
we utilized 3 distinct, commonly applied statistical approaches to
identify those gene loci (from each of the three statistical approaches
and across the 2 series) that overlapped in differentiating invasive
and non-invasive disease. Five loci (FRZB_E186, HOXB2_P99,
KRT13_P676, RIPK1_P868, STAT5A_P704) were found to be
associated with invasive disease in all three statistical approaches.
For four of these loci (FRZB, STAT5A, KRT13, and HOXB2),
bisulfite pyrosequencing assays were able to be designed, and were
used to confirm the array findings in a subset of bladder tumors
examined on the array. A pyrosequencing assay for RIPK1 could
not be successfully designed. For all CpG sites examined, as well as
the mean across sites for FRZB, KRT13, and HOXB2, we observed
significantly greater methylation in invasive compared to non-
invasive tumors, consistent with the array results (Figure S2A,
S2C, S2D). For STAT5A, we confirmed the significantly greater
extent of methylation at the specific CpG site measured by the
array, but did not observe this association in the neighboring CpG
sites (Fig S2B), and so this loci was not further investigated.
Treatment of a Bladder Cancer Cell Line with Methylation
Inhibitor Leads to Re-expression of HOXB2
Pyrosequencing was performed to determine the methylation
status of HOXB2, FRZB, and KRT13 in bladder cancer cell lines
HTB-9 and UM-UC3. HTB-9 had a HOXB2 methylation extent
of 68.9, similar to what had been observed amongst primary
bladder tumor samples, and thus was chosen for further
examination. Treatment of HTB-9 cells with 1 or 2 mM 5-aza-
29-deoxycytidine led to an increase of greater than 100 fold
expression of HOXB2 compared to mock-treated cells (Figure 2).
HOXB2 Methylation is independently associated with
invasive bladder cancer
Pyrosequencing of the promoter regions of FRZB, KRT13, and
HOXB2 was performed in an independent series of 263 bladder
tumor patients not examined on the array as well as on 4 non-
diseased tumor samples obtained from the NDRI. The extent of
methylation at the pyrosequenced regions in non-diseased bladder
epithelium, non-invasive tumors to invasive tumors is depicted on
Figure 3, and reveals significant differences in methylation across
the 3 categories for each of the genes (HOXB2 P,0.00001, KRT13
P,0.05, FRZB P,0.003, Kruskal Wallis Test). Methylation of
HOXB2 and KRT13 are each significantly greater in invasive
compared to non-invasive tumors (protected Wilcoxon rank sums
test, P,0.00001 and P,0.02 respectively). TP53 immunohisto-
chemical (IHC) staining intensity has been previously associated
with a more aggressive disease [19,20], and we included this
variable when we performed logistic regression predicting invasive
disease, for each of the loci individually, dichotomizing the
methylation extent at the median, and controlling for other
potential confounders. In models controlled for age, gender, and
TP53 immunohistochemical staining intensity of the tumor, only
HOXB2 promoter methylation demonstrated an independent
association with invasive tumors (Table 2). Tumors with HOXB2
methylation had an OR of 7.7 (95% CI 3.3, 18.2) for being an
Table 1. Demographics of the subject populations.
Characteristics
Series I – Profiled on Array
(n=73)
Series 2 – Profiled on Array
(n=264)
Series 3 – Used for Confirmation
(n=245)
Age, mean 6SD 62.169.3 65.169.9 62.969.1
Gender, n (%)
Male 53 (73%) 200 (76%) 190 (78%)
Female 20 (27%) 64 (24%) 55 (22%)
Invasive Stage Tumor, n (%)*
Non-invasive 42 (58%) 189 (72%) 181 (74%)
Low Grade (1–2) 35 (83%) 162 (86%) 158 (87%)
High Grade (3) 7 (17%) 27 (14%) 23 (13%)
Invasive 31 (42%) 75 (28%) 64 (26%)
Tumor TP53 IHC Staining Intensity, n (%)*
Low (1,2) 50 (68%) 195 (74%) 189 (77%)
High (3+) 23 (32%) 69 (26%) 55 (23%)
*1 tumor in series 1 and one in the confirmation series did not have TP53 IHC staining data.
doi:10.1371/journal.pone.0012334.t001
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loci as well as TP53 IHC staining intensity and patient age and
gender, where HOXB2 methylation was associated with an 8.6 fold
increased risk of being an invasive tumor (95% CI 3.4, 21.7).
Methylation of HOXB2, FRZB, and KRT13 are Associated
with Aggressive Non-invasive Bladder Cancer
As we are interested in determining how methylation contrib-
utes to progression and aggressiveness of tumors, we examined the
association between methylation extent and tumor grade within
the non-invasive tumors. Figure 4 demonstrates that there is
significantly greater extent of methylation of HOXB2 (P,0.01),
KRT13 (P,0.01) and KRT13 (P=0.0001) in high grade (3)
compared to low grade (1,2) non-invasive tumors. To control for
potential confounding, we performed multivariable logistic
regression analysis to examine the association between gene
promoter methylation extent and tumor grade. Initially, we
modeled each gene promoter individually, and observed signifi-
Figure 1. Methylation bead array profiles distinguish non-invasive and invasive bladder tumors. (A) Scatterplot of average methylation
beta values in non-invasive bladder tumors (x-axis) and average methylation beta values in invasive tumors (y-axis) in series 1 (n=73) and series 2
(n=264) samples. (B) Recursive partition mixture models of each series result in 4 classes separated by red vertical lines, with the width of the classes
corresponding to the number of samples in each class. Loci are represented as rows with the mean methylation for the class depicted. Above each
class is the prevalence of invasive tumors (n invasive/total n) within the class. Methylation profiles significantly distinguish bladder tumor from non-
diseased bladder epithelium (P,0.00001).
doi:10.1371/journal.pone.0012334.g001
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KRT13 (OR 3.3, 95% CI 1.1, 10.1), but only a borderline
significant association between HOXB2 methylation and high
tumor grade (OR 2.6, 95% CI 0.9, 6.9, Table S2). We then
examined the additive effects of methylation of these 3 loci by
modeling the association between methylation of all three loci
compared to having none, 1, or 2 methylated and high-grade non-
invasive disease (Table 3). Controlled for age, gender, and TP53
IHC staining intensity, methylation of all 3 loci was associated with
a significant 7.4 fold increased risk of being a high grade tumor
(95% CI 2.5, 22.1).
Discussion
Compared to gene-expression based markers, DNA methylation
patterns are more stable and can be detected using various
approaches requiring relatively small amounts of patient materials.
In addition, these markers can be objectively identified and
quantified, providing potential improvement to reliability in
histological subjective diagnoses such as tumor grades or
compared to immunohistochemical staining patterns which rely
on individual interpretation of intensity and location of staining.
For example, the markers identified and independently validated
in this study hold promise as biomarkers useful in bladder cancer
screening and follow-up for recurrence and progression and could
be applied and tested for clinical utility in easy to collect urine
sediments [9,10,11,13,21]. In addition, discovery of genes and
pathways epigenetically altered in bladder tumors suggest novel
targets for therapeutic intervention, especially when considering
the poor prognosis associated with invasive bladder cancers.
Identification of important and useful DNA methylation based
markers is not without challenge, particularly as there is often a
high degree of correlation between these alterations [22].
Therefore appropriate statistical approaches must be utilized to
examine these alterations and to identify those alterations with the
greatest clinical utility. We believe that our 2 stage approach
provides for the most robust and generalizable identification of
DNA methylation alterations which can be further examined in
prospective studies. Using several different statistical approaches,
our selection strategy for informative markers allowed us to
identify a manageable number of potentially useful and robust
biomarkers for laboratory validation as well as replication in
independent samples. Most importantly, our validation of these
markers in an independent group of patients provides compelling
evidence of their potential utility and biological importance.
Previous studies examining panels of candidate genes have
identified specific genes and panels of loci which are predictive of
both the presence of tumor when examined in urine sediment [23]
and the progression from non-invasive to invasive disease
[15,24,25,26] when examined within the tumor tissue. Specific
genes such as RASSF1A, RARB, BAMBI and the SFRP family have
been associated with higher grade and higher stage bladder cancer
[8,27,28]. Our strategy did not identify these specific genes, and
this discrepancy may be due to a number of differences between
our approach and those previously utilized. We have made use of
a population-based case series sample, while many previous studies
have utilized hospital-based convenience series, and thus may have
had some bias introduced in the samples examined. The array
platform used in this study is limited in that it examines only a
subset of all genes and only 1 or 2 specific CpG sites for those
genes, and thus may miss the specific genes of loci previously
described. Finally, our analytical approach, as it is based on the
Figure 2. HOXB2 is re-expressed following treatment of HTB-9 bladder cancer cells with 5-aza-29deoxycytidine. Quantitative RT-PCR
analysis was used to determine the gene expression of HOXB2 in human bladder carcinoma cell line HTB-9, following a 5-day treatment with 1 or
2 mM 5-aza-29-deoxycytidine or mock treatment. Bars represent the mean fold change in expression compared to mock treatment for 4 or 6 replicate
experiments, and error bars denote the standard errors.
doi:10.1371/journal.pone.0012334.g002
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those used in candidate analyses, but hypermethylation of those
previously described candidates, may, in fact, be highly correlated
to the methylation patterns identified herein. Further study
combining previously identified loci with our own new targets in
a prospective fashion is needed to more definitively determine
those loci with the greatest clinical utility.
The biologic underpinnings of non-invasive yet recurrent
disease versus invasive disease remain to be fully elucidated [29].
Our findings indicate that there are large differences in
methylation between invasive and non-invasive tumors, with
invasive tumors exhibiting a general increase in methylation
compared to non-invasive tumors. As DNA methylation at any
one CpG is a binary measure (either the cytosine is methylated or
not) the difference in the degree of methylation may reflect
potentially greater homogeneity in the selection of epigenetically
altered cells in the development of invasive disease, a result
consistent with our previous work examining only a limited panel
of gene promoters in a single series of bladder tumors [14]. This
greater degree of methylation may be driving the features of the
invasive phenotype, or alternatively may be a consequence of
selective pressures related to this phenotype. Although our
approach in examining incident disease cannot fully distinguish
these possibilities, it provides data illustrative of the urgent need for
further examination of this epigenetic phenomenon.
Identification of specific genes whose DNA methylation pattern
is associated with tumor phenotypes, including stage and grade
also illuminates the particularly important biological processes and
pathways required for genesis of these histologically defined tissue
states. The FRZB gene (also known as SFRP3) is a member of the
secreted frizzled receptor family of soluble proteins which binds to
and antagonizes the WNT receptor. We and others have
previously shown that hypermethylation of SFRP genes is strongly
and significantly associated with invasive bladder cancer, con-
firming the importance of this pathway in this phenotype [8,12].
Of the SFRP genes, only SFRP1, (in addition to FRZB) is profiled
on the array, and at a different CpG location than the primers
used in our and previous reports of its methylation [8,30]. This
may explain why this loci was not identified in our screening
approach. Additional, more genomically dense investigation of the
WNT pathway is warranted, as this may suggest a novel route for
therapeutic intervention for this disease.
HOXB2 is a member of the homeobox family of transcription
factors, and is encoded on chromosome 17 as part of a gene cluster
with other HOX family members. Interestingly, we observe that
non-diseased bladder epithelium exhibits a similar extent of
Figure 3. Bisulfite pyrosequencing reveals a greater extent of methylation in invasive bladder cancer. The mean (filled circle) and 95%
confidence intervals of the extent of methylation of the promoter regions of (A) FRZB, (B) KRT13, and (C) HOXB2 are depicted (y-axis) comparing non-
diseased bladder epithelium, non-invasive tumors and invasive tumors (x-axis). The differences in the extent of methylation across these groups is
significantly different (Kruskal-Wallis test), for HOXB2 (P,0.00001) and KRT13 (P,0.04), and FRZB (P,0.003). Comparisons specifically of noninvasive
compared to invasive disease also revealed significant differences for HOXB2 *P,0.00001 and KRT13 **P,0.02.
doi:10.1371/journal.pone.0012334.g003
Bladder Cancer Epigenetics
PLoS ONE | www.plosone.org 5 August 2010 | Volume 5 | Issue 8 | e12334methylation at HOXB2 and KRT13 as the non-invasive disease,
while at FRZB the non-diseased tissue has a significantly lower
extent of methylation than either of the 2 tumor types. We also
observe, in the human bladder carcinoma cell line HTB-9, which
demonstrates an extent of methylation similar to that observed in
invasive tumors, that treatment with the methylation inhibitor 5-
aza-29-deoxycytidine leads to increased expression of HOXB2,
suggesting that methylation of this gene may be functionally
leading to the inactivation of this gene. The results in HOXB2 are
consistent with the literature which has described a bivalent
domain structure of the chromatin of homeobox genes, wherein
both pluripotent and terminally differentiated tissue exhibit marks
of both active and repressive chromatin within the same region
[31,32], and thus an intermediate extent of DNA methylation.
Invasive bladder cancers appear targeted for hypermethylation of
this region, a phenomenon previously reported across polycomb
group controlled genes in colorectal cancer cells [33]. Such a
differential alteration of a key developmental gene may be critical
in defining the phenotypes of these tumors and explain the
behavior and outcome from these disparate forms of this disease.
KRT13 encodes cytokeratin-13 which has been shown to have
specific expression in cervical squamous tumors and in mucinous
cervical type adenocarcinomas [34]; to our knowledge, epigenetic
alterations to this gene have not been reported. Epigenetic
alteration of this gene may affect its expression pattern, and such
changes may be signs of a more de-differentiated phenotype,
considered characteristic of aggressive, high grade tumors.
We demonstrated in an independent confirmation series of
tumors that the extent of methylation of HOXB2 and FRZB is
associated with tumor grade, independent of each other and of
TP53 protein immunohistochemical staining. TP53 staining has
previously been examined and has been touted as a useful
prognostic marker in this disease [35,36,37], although there is
conflicting data on its utility [36,38,39,40]. A recent meta-analysis
examining its utility suggests that there is not appropriate evidence
to suggest utilizing this marker clinically [20], as it may provide no
addition prognostic information other than a strong association
with the invasive phenotype of the disease [41,42]. We cannot yet
suggest that the markers discovered using our approach hold any
more clinical utility than pathological grading and staging of
tumors, but we believe that our data suggest specific cellular
pathways that are disrupted in this disease. Thus, these pathways
could be explored intensively as novel targets for therapeutic
strategies. In addition, we suggest that future work, examining the
utility of these markers in a prospective fashion is needed, as they
may be useful in determining which tumors may progress. Indeed,
these markers might also contribute to clinical efforts to follow
patients with less invasive methods, to determine if their tumor has
recurred or progressed, thereby requiring more aggressive
treatment approaches.
Methods
Study Population and Sample Ascertainment
All study participants provided written informed consent under
the approval of the institutional review boards of Dartmouth
Medical School and Brown University. We utilized two,
independent, non-consecutive population-based series of bladder
cancer cases. The first, consisting of tumors from 344 individuals
involved in a case-control study of incident bladder cancer in New
Hampshire, diagnosed between July 1994 and June 1998 [43], and
the second consisting of tumors from 264 individuals diagnosed
between January 1, 2002 to July 30, 2004 [44]. Although separate
in time and scope, these two studies utilized identical recruitment
procedures and study personnel as well as identical protocols for
the ascertainment of pathology materials for molecular examina-
Table 2. Individual gene methylation associations with invasive bladder cancer.
Non-
invasive
n( % )
Invasive
n( % )
Invasive
OR
(95% CI)*
Non-
invasive
n( % )
Invasive
n( % )
Invasive
Disease OR
(95% CI)*
Non-
invasive
n( % )
Invasive
n( % )
Invasive
Disease OR
(95% CI)*
Non-
invasive
n( % )
Invasive
n( % )
Invasive
Disease OR
(95% CI){
Total N 171 61 170 62 177 61 162 57
HOXB2
Negative
(#median)
110 (93) 8 (7) 1.0
(referent)
– – – – – – 104 (94) 7 (6) 1.0 (referent)
Positive
(.median)
61 (54) 53 (46) 7.7
(3.3, 18.2)
– – – – – – 58 (54) 50 (46) 8.6 (3.4, 21.7)
KRT13
Negative
(#median)
– – – 91 (80) 22 (20) 1.0 (referent) – – – 86 (82) 19 (18) 1.0 (referent)
Positive
(.median)
– – – 79 (66) 40 (34) 1.3 (0.7, 2.7) – – – 76 (67) 38 (33) 1.0 (0.4, 2.3)
FRZB
Negative
(#median)
– – – – – – 93 (80) 24 (20) 1.0 (referent) 84 (78) 23 (22) 1.0 (referent)
Positive
(.median)
– – – – – – 84 (69) 37 (31) 1.4 (0.7, 2.7) 78 (70) 34 (30) 0.9 (0.4, 2.0)
TP53 IHC Staining Intensity
Low (,3) 154 (86) 26 (14) 1.0 (referent) 154 (86) 26 (14) 1.0 (referent) 160 (86) 26 (14) 1.0 (referent) 146 (85) 26 (15) 1.0 (referent)
High (3+) 17 (33) 35 (67) 7.4 (3.4, 16.0) 16 (31) 36 (69) 12.4 (5.9, 25.9) 17 (33) 35 (67) 12.1 (5.9, 24.9) 16 (34) 31 (66) 6.1 (2.7, 13.8)
*Model is adjusted for age, gender, and TP53 Staining Intensity.
{Model is adjusted for age, gender, each gene methylation variable, and TP53 Staining Intensity and includes only those subjects with data for all covariates.
doi:10.1371/journal.pone.0012334.t002
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pathologist (A.R.S.) and classified according to the 1973 and 2004
World Health Organization guidelines for bladder tumors. The
study pathologist identified the appropriate block from which the
tumor samples used in these analyses were obtained, and the
proportion of malignant cells in each sample was estimated. All
samples used in the examination contained .75% tumor sample.
Carcinoma in-situ was excluded from analysis due to limited
sample size. Table 1 describes the characteristics of the subjects
included in the final analysis. In addition, four non-diseased
bladder epithelium samples were obtained from the National
Disease Research Interchange (NDRI) all from autopsy specimens
of individuals who did not have a diagnosis of cancer.
DNA Extraction and Methylation Analysis
Tumor sections with the greatest proportion of malignant tissue
were selected by the study pathologist for use in our molecular
analyses. DNA was extracted and sodium bisulfite modified
following standard procedures as described in Marsit, et al. [18]. A
total of 82 tumors from the first series and all 264 tumors from the
second series were profiled for the methylation status at 1505 CpG
loci using the Illumina GoldenGateH methylation bead arrays.
Bead arrays were run at the UCSF Institute for Human Genetics,
Genomics Core Facility according to the manufacturer’s protocol
and as described in Bibikova, et al. [45].
Statistical analysis
We assembled data with BeadStudio Methylation software from
the array manufacturer (Illumina, San Diego, CA) and quality
Figure 4. Bisulfite pyrosequencing demonstrates that extent of methylation is associated with tumor grade in non-invasive tumors.
The mean (filled circle) and 95% confidence intervals of the extent of methylation of the promoter regions of (A) FRZB, (B) KRT13, and (C) HOXB2 are
depicted (y-axis) comparing low (1,2) to high (3+) grade tumors (x-axis). P-values resulting from the Wilcoxon Rank Sums demonstrate that these
differences are significant for HOXB2 (P,0.01), KRT13 (P,0.01) and FRZB (P=0.0001).
doi:10.1371/journal.pone.0012334.g004
Table 3. Methylation of HOXB2, FRZB and KRT13 is
independently associated with high grade disease in
non-invasive bladder cancer.
Grade 1, 2 Grade 3 Grade 3 OR
n(%) n(%) (95% CI)
Total N 143 19
HOXB2, FRZB, and KRT13
Methylation .Median
None, 1, or 2 Genes 125 (94) 8 (6.0) 1.0 (referent)
All 3 Genes 18 (62) 11 (38) 7.4 (2.5, 22.1)
TP53 IHC Staining
Intensity
Low (,3) 133 (91) 13 (9.0) 1.0 (referent)
High (3+) 10 (62) 6 (38) 4.7 (1.3, 17.4)
Each model is controlled for variables in columns, as well as age and gender.
doi:10.1371/journal.pone.0012334.t003
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seven samples (9%), where .75% of loci had a detection p-value
.1*10
25, being dropped from analysis. A similar quality control
for CpG loci eliminated those loci with median detection p-value
.0.05 (n=8, 0.5%).
Subsequent analyses were carried out in The R Package. For
exploratory/visualization purposes, hierarchical clustering using
the Manhattan metric and average linkage was performed. For
locus by locus analyses, associations at individual CpG loci
were tested with a generalized linear model (GLM). Under
the assumption that the average beta values follow a beta
distribution [46], a quasi-binomial model (logit link, binomial
variance, and non-unit scale parameter) was used; note that the
logit link function imposes an appropriate constraint on the
mean average beta. To adjust for multiple comparisons in
scanning the 1413 autosomal CpG loci, P-values for associations
between average beta and invasive disease used false discovery
rate correction and q-values computed by the qvalue package in
R. An FDR q-value of ,0.05 was considered significant for this
examination.
Random Forests [47](http://www.math.usu.edu/,adele/forests/),
was used to build classifiers of invasive stage (versus noninvasive) by
CpG average beta values. Analysis was conducted in R using the
randomForest package (version 4.5-18) by Liaw and Wiener. At
each node of the tree, a random sample of m out of the total M
variables was chosen and the best split is found among the m
variables. The default value for m in the Random Forest R
package is
ﬃﬃﬃﬃﬃﬃ
M
p
. In this analysis we tested a range of m from half
of
ﬃﬃﬃﬃﬃﬃ
M
p
to two times
ﬃﬃﬃﬃﬃﬃ
M
p
and used m that gave the lowest
prediction error; in this case m=38. The OOB error rate is the
percentage of time the RF prediction is incorrect. A test for
association between methylation (predictors) and sample type was
conducted by comparing the OOB obtained on the data set with
the null distribution of OOB errors obtained by permuting
sample type labels and running the RF procedure 100 times. We
also used the second series of 264 tumors as a validation set,
computing the error rate as each tree is constructed, to obtain an
estimated error rate independent of the first series. Finally, we
used the variable importance scores, percent change in mean
squared error (MSE), to identify loci that had the greatest
influence on classification, by choosing those loci whose percent
change in MSE was greater than 5%.
For inference, data were clustered using a mixture model [48] with
a mixture of beta distributions [49], and the number of classes was
determined by Bayesian information criterion (BIC) [50,51]. The
mixture model was fit by recursively partitioning the data using a 2-
class mixture model, with a variant of BIC used as a criterion for the
split, as described in [46]. Class membership was obtained from the
mixture model using an empirical Bayes procedure, and subsequent
associations with invasive stage were tested via permutation test with
10,000 permutations each using the standard chi-square goodness-of-
fit test. The output of mixture models includes a class-specific beta
distribution Fjk for each locus j and class k. These distributions
imply a receiver operating curve (ROC) for distinguishing two
classes k and l by the relation ROCjkl(r)~Fjk(F{1
jl (r)) or
ROCjkl(r)~1{Fjk(F{1
jl (1{r)), whichever curve lies above the
identity line. In either case, the area-under-the-ROC (AUC),
computed as AUCjkl~
1
2
{
ð1
0
Fjk(F{1
jl (r))dr
       
       z
1
2
, which can be
used to determine the influence of locus j on the distinction between
classes k and l. A similar procedure can be used to distinguish class k
from the others: we use a normal approximation Gjk for the
distribution of the combined classes other than k,a n dc o m p u t e
AUCjkl~
1
2
{
ð1
0
Gjk(F{1
jk (r))dr
       
       z
1
2
. We then ranked each locus j
by its computed AUCjk,a n ds e l e c t e dt h o s ew i t hA U C .0.90.
To identify loci for subsequent validation as predictors of
invasive vs. non-invasive disease, we computed the intersection of
the loci that were most significant (Q,0.05) in the locus-by-locus
analysis, the top ranking loci from the RF analysis (% change in
MSE.6%), and the loci having AUC.0.75 for distinguishing the
class of interest compared to others in each tumor series, and then
identified those loci overlapping in both series.
Bisulfite Pyrosequencing
Quantification of cytosine percent methylation was performed by
pyrosequencing bisulfite-converted DNA using the PyroMark MD
pyrosequencing system (Qiagen, Valencia, CA). Specific pyrose-
quencing primers were designed to amplify array CpG sites and as
many downstream CpGs as conditions permitted (1 to 5 additional)
using Biotage Assay Design Software v1.0.6 (Qiagen). Assays
designs were attempted for all 5 of the loci identified as overlapping
from the 3 analysis strategies and assays were successfully designed
for 4 of the loci. Primer details and the genomic location of the
region sequenced relative to the transcription start site are provided
in Table S3. The sequences used were based on the reference
sequence assembly 36.1. All PCR reactions, performed using
Qiagen Hot Star Taq polymerase, included a no template control,
unmodified DNA control, and 7 standardized percent methylation
controls (0%, 15%, 25%, 45%, 65%, 75%, and 100%) derived from
Qiagen EpiTectH PCR control DNA set samples. Sequencing
reactions used 10ml of PCR product and were run according to
instrument/manufacturer protocols (Biotage).
Statistical Analysis of Pyrosequencing Data
Associations between pyrosequencing percent methylation values
at individual CpG sites were examined using the Spearman rank
correlation. The mean value of CpG methylation across the
examined CpG sites was used in further analyses. To examine the
association between methylation extent as a continuous variable and
tumor grade, we utilized the non-parametric Kruskal-Wallis one-way
analysis of variance. To adjust for potential confounders and to
determine the odds ratio (OR) and 95% confidence interval (CI) for
high grade disease, we used multivariable unconditional logistic
regression analysis to examine the association between methylation
extent (in quartiles) at individual sites and tumor grade (grade 1 vs.
grade 2, 3, 4), with adjustment for potential confounders. We also
included a term to control for percent of tumor cells within sample in
the model, and found that there were no significant changes in the
effect estimates or significance of the main effects, and thus this term
was not considered a confounder as was removed from the model.
Cell Culture and Drug Treatment
Human bladder carcinoma cell lines UMUC3 and HTB-9 were
purchased from the American Type Culture Collection (Manassas,
VA). Cell lines were grown in their respective vendor-recom-
mended culture media at 37uC and 5% CO2 and passaged every
3–5 days. Approximately 1 million cells were harvested from each
and DNA isolated and sodium bisulfite modified as above to
examine methylation status of the candidate loci. 5-aza-29-
deoxycytidine was obtained from Sigma-Aldrich (St. Louis,
MO), and was prepared in sterile DMSO. The concentrations
used for the experiment were chosen to mimic those observed
clinically in human plasma [52] and that did not result in
significant loss in cell viability. For experiments, cells were seeded
24 hours before drug treatment, 20,000 cells per well into a 6-well
cell culture plate. The media was replaced with that containing 5-
Bladder Cancer Epigenetics
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harvested on day 5 and immediately subjected to RNA isolation.
RNA Isolation and Quantitative RT-PCR Analysis
Total RNA was isolated from cells using the Qiagen RNEasy
RNA isolation system, following manufacturer’s protocols, and
including an on-column DNAse digestion. The cDNA was
prepared from 150 ng total RNA using the Taqman Gene
Expression system (Applied Biosystems, Carlsbad, CA). cDNA,
diluted 1:5 was subjected to RT-PCR for HOXB2
(Hs01911157_s1) and ACTB (hu ACTB) as the referent gene
using pre-designed Taqman primers and probes on an ABI 7500
Fast Real Time PCR system (Applied Biosystems). All RT-PCRs
were run in triplicate and no-template and no reverse transcription
controls were included for each assay. Fold change was calculated
using the Pfaffl method [53].
Supporting Information
Figure S1 Diagram of the methodology used in the selection of
loci for follow-up analyses and validation.
Found at: doi:10.1371/journal.pone.0012334.s001 (0.27 MB TIF)
Figure S2 Confirmation of DNA methylation of FRZB (A),
STAT5A (B), KRT13 (C), and HOXB2 (D) by pyrosequencing in
samples analyzed on the array. Dots represent percent methylation
at each position examined (POS) in non-invasive (N) compared to
invasive (I) tumor tissue. The gray box encloses the position which
represents that position examined on the array. *P,0.05,
**P,0.0001.
Found at: doi:10.1371/journal.pone.0012334.s002 (1.68 MB TIF)
Table S1 Results of locus by locus analysis comparing invasive
to non-invasive bladder cancers with Q,0.001.
Found at: doi:10.1371/journal.pone.0012334.s003 (0.56 MB
PDF)
Table S2 Individual gene promoter methylation is associated
with high grade in non-invasive bladder cancer.
Found at: doi:10.1371/journal.pone.0012334.s004 (0.05 MB
PDF)
Table S3 Primer sequences used for bisulfite pyrosequencing
reactions.
Found at: doi:10.1371/journal.pone.0012334.s005 (0.08 MB
PDF)
Author Contributions
Conceived and designed the experiments: CJM EAH BCC HHN JKW
MRK KTK. Performed the experiments: CJM BCC LG SZ. Analyzed the
data: CJM EAH BCC MRW JLW ARS MRK. Contributed reagents/
materials/analysis tools: EAH SZ JKW ASA ARS MRK KTK. Wrote the
paper: CJM EAH BCC MRW HHN JLW JKW ARS MRK KTK.
References
1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics, 2009.
CA Cancer J Clin 59: 225–249.
2. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R (2003) The health
economics of bladder cancer - A comprehensive review of the published
literature. Pharmacoeconomics 21: 1315–1330.
3. Ockrim JL, Abel PD (2007) Treatment Options in Superficial (pTa/pT1/CIS)/
Bladder Cancer. In: Waxman J, ed. Urological cancers in clinical practice.
London: Springer. pp 75–101.
4. Iacobuzio-Donahue CA (2009) Epigenetic changes in cancer. Annu Rev Pathol
4: 229–249.
5. Catto JW, Miah S, Owen HC, Bryant H, Myers K, et al. (2009) Distinct
microRNA alterations characterize high- and low-grade bladder cancer. Cancer
Res 69: 8472–8481.
6. Mathews LA, Crea F, Farrar WL (2009) Epigenetic gene regulation in stem cells
and correlation to cancer. Differentiation 78: 1–17.
7. Esteller M (2003) Cancer epigenetics: DNA methylation and chromatin
alterations in human cancer. Adv Exp Med Biol 532: 39–49.
8. Marsit CJ, Karagas MR, Andrew A, Liu M, Danaee H, et al. (2005) Epigenetic
inactivation of SFRP genes and TP53 alteration act jointly as markers of invasive
bladder cancer. Cancer Res 65: 7081–7085.
9. Yu J, Zhu T, Wang Z, Zhang H, Qian Z, et al. (2007) A novel set of DNA
methylation markers in urine sediments for sensitive/specific detection of
bladder cancer. Clin Cancer Res 13: 7296–7304.
10. Hoque MO, Begum S, Topaloglu O, Chatterjee A, Rosenbaum E, et al. (2006)
Quantitation of promoter methylation of multiple genes in urine DNA and
bladder cancer detection. J Natl Cancer Inst 98: 996–1004.
11. Sathyanarayana UG, Maruyama R, Padar A, Suzuki M, Bondaruk J, et al.
(2004) Molecular detection of noninvasive and invasive bladder tumor tissues
and exfoliated cells by aberrant promoter methylation of laminin-5 encoding
genes. Cancer Res 64: 1425–1430.
12. Stoehr R, Wissmann C, Suzuki H, Knuechel R, Krieg RC, et al. (2004)
Deletions of chromosome 8p and loss of sFRP1 expression are progression
markers of papillary bladder cancer. Lab Invest 84: 465–478.
13. Urakami S, Shiina H, Enokida H, Kawakami T, Kawamoto K, et al. (2006)
Combination analysis of hypermethylated Wnt-antagonist family genes as a
novel epigenetic biomarker panel for bladder cancer detection. Clin Cancer Res
12: 2109–2116.
14. Marsit CJ, Houseman EA, Schned AR, Karagas MR, Kelsey KT (2007)
Promoter hypermethylation is associated with current smoking, age, gender and
survival in bladder cancer. Carcinogenesis 28: 1745–1751.
15. Aleman A, Adrien L, Lopez-Serra L, Cordon-Cardo C, Esteller M, et al. (2008)
Identification of DNA hypermethylation of SOX9 in association with bladder
cancer progression using CpG microarrays. Br J Cancer 98: 466–473.
16. Christensen BC, Houseman EA, Godleski JJ, Marsit CJ, Longacker JL, et al.
(2009) Epigenetic profiles distinguish pleural mesothelioma from normal pleura
and predict lung asbestos burden and clinical outcome. Cancer Res 69:
227–234.
17. Killian JK, Bilke S, Davis S, Walker RL, Killian MS, et al. (2009) Large-scale
profiling of archival lymph nodes reveals pervasive remodeling of the follicular
lymphoma methylome. Cancer Res 69: 758–764.
18. Marsit CJ, Christensen BC, Houseman EA, Karagas MR, Wrensch MR, et al.
(2009) Epigenetic profiling reveals etiologically distinct patterns of DNA
methylation in head and neck squamous cell carcinoma. Carcinogenesis 30:
416–422.
19. Kelsey KT, Hirao T, Hirao S, Devi-Ashok T, Nelson HH, et al. (2005) TP53
alterations and patterns of carcinogen exposure in a U.S. population-based study
of bladder cancer. Int J Cancer 117: 370–375.
20. Malats N, Bustos A, Nascimento CM, Fernandez F, Rivas M, et al. (2005) P53 as
a prognostic marker for bladder cancer: a meta-analysis and review. Lancet
Oncol 6: 678–686.
21. Kim YK, Kim WJ (2009) Epigenetic markers as promising prognosticators for
bladder cancer. Int J Urol 16: 17–22.
22. Marsit CJ, Houseman EA, Christensen BC, Eddy K, Bueno R, et al. (2006)
Examination of a CpG island methylator phenotype and implications of
methylation profiles in solid tumors. Cancer Res 66: 10621–10629.
23. Yates DR, Rehman I, Meuth M, Cross SS, Hamdy FC, et al. (2006)
Methylational urinalysis: a prospective study of bladder cancer patients and
age stratified benign controls. Oncogene 25: 1984–1988.
24. Yates DR, Rehman I, Abbod MF, Meuth M, Cross SS, et al. (2007) Promoter
hypermethylation identifies progression risk in bladder cancer. Clin Cancer Res
13: 2046–2053.
25. Aleman A, Cebrian V, Alvarez M, Lopez V, Orenes E, et al. (2008)
Identification of PMF1 methylation in association with bladder cancer
progression. Clin Cancer Res 14: 8236–8243.
26. Kim EJ, Kim YJ, Jeong P, Ha YS, Bae SC, et al. (2008) Methylation of the
RUNX3 promoter as a potential prognostic marker for bladder tumor. J Urol
180: 1141–1145.
27. Jarmalaite S, Jankevicius F, Kurgonaite K, Suziedelis K, Mutanen P, et al.
(2008) Promoter hypermethylation in tumour suppressor genes shows association
with stage, grade and invasiveness of bladder cancer. Oncology 75: 145–
151.
28. Khin SS, Kitazawa R, Win N, Aye TT, Mori K, et al. (2009) BAMBI gene is
epigenetically silenced in subset of high-grade bladder cancer. Int J Cancer 125:
328–338.
29. Dinney CP, McConkey DJ, Millikan RE, Wu X, Bar-Eli M, et al. (2004) Focus
on bladder cancer. Cancer Cell 6: 111–116.
30. Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD, et al. (2004)
Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in
colorectal cancer. Nat Genet 36: 417–422.
31. Azuara V, Perry P, Sauer S, Spivakov M, Jorgensen HF, et al. (2006) Chromatin
signatures of pluripotent cell lines. Nat Cell Biol 8: 532–538.
32. Bernstein BE, Mikkelsen TS, Xie X, Kamal M, Huebert DJ, et al. (2006) A
bivalent chromatin structure marks key developmental genes in embryonic stem
cells. Cell 125: 315–326.
Bladder Cancer Epigenetics
PLoS ONE | www.plosone.org 9 August 2010 | Volume 5 | Issue 8 | e1233433. Widschwendter M, Fiegl H, Egle D, Mueller-Holzner E, Spizzo G, et al. (2007)
Epigenetic stem cell signature in cancer. Nat Genet 39: 157–158.
34. Carrilho C, Alberto M, Buane L, David L (2004) Keratins 8, 10, 13, and 17 are
useful markers in the diagnosis of human cervix carcinomas. Hum Pathol 35:
546–551.
35. Serth J, Kuczyk MA, Bokemeyer C, Hervatin C, Nafe R, et al. (1995) p53
immunohistochemistry as an independent prognostic factor for superficial
transitional cell carcinoma of the bladder. Br J Cancer 71: 201–205.
36. Gardiner RA, Walsh MD, Allen V, Rahman S, Samaratunga ML, et al. (1994)
Immunohistological expression of p53 in primary pT1 transitional cell bladder
cancer in relation to tumour progression. Br J Urol 73: 526–532.
37. Watanabe R, Tomita Y, Nishiyama T, Tanikawa T, Sato S (1994) Correlation
of p53 protein expression in human urothelial transitional cell cancers with
malignant potential and patient survival. Int J Urol 1: 43–48.
38. Esuvaranathan K, Chiong E, Thamboo TP, Chan YH, Kamaraj R, et al. (2007)
Predictive value of p53 and pRb expression in superficial bladder cancer patients
treated with BCG and interferon-alpha. Cancer 109: 1097–1105.
39. Fleshner N, Kapusta L, Ezer D, Herschorn S, Klotz L (2000) p53 nuclear
accumulation is not associated with decreased disease-free survival in patients
with node positive transitional cell carcinoma of the bladder. J Urol 164:
1177–1182.
40. Grossman HB, Liebert M, Antelo M, Dinney CP, Hu SX, et al. (1998) p53 and
RB expression predict progression in T1 bladder cancer. Clin Cancer Res 4:
829–834.
41. Hemal AK, Khaitan A, Dinda AK, Gupta NP, Seth A, et al. (2003) Prognostic
significance of p53 nuclear overexpression in patients of muscle invasive urinary
bladder carcinoma treated with cystectomy. Urol Int 70: 42–46.
42. Kelsey KT, Hirao T, Schned A, Hirao S, Devi-Ashok T, et al. (2004) A
population-based study of immunohistochemical detection of p53 alteration in
bladder cancer. Br J Cancer 90: 1572–1576.
43. Karagas MR, Tosteson TD, Blum J, Morris JS, Baron JA, et al. (1998) Design of
an epidemiologic study of drinking water arsenic exposure and skin and bladder
cancer risk in a U.S. population. Environ Health Perspect 106 Suppl 4:
1047–1050.
44. Baris D, Karagas MR, Verrill C, Johnson A, Andrew AS, et al. (2009) A case-
control study of smoking and bladder cancer risk: emergent patterns over time.
J Natl Cancer Inst 101: 1553–1561.
45. Bibikova M, Lin Z, Zhou L, Chudin E, Garcia EW, et al. (2006) High-
throughput DNA methylation profiling using universal bead arrays. Genome
Res 16: 383–393.
46. Houseman EA, Christensen BC, Yeh RF, Marsit CJ, Karagas MR, et al. (2008)
Model-based clustering of DNA methylation array data: a recursive-partitioning
algorithm for high-dimensional data arising as a mixture of beta distributions.
BMC Bioinformatics 9: 365.
47. Breiman L (2001) Random Forests. Machine Learning 45: 5–32.
48. Siegmund KD, Laird PW, Laird-Offringa IA (2004) A comparison of cluster
analysis methods using DNA methylation data. Bioinformatics 20: 1896–1904.
49. Ji Y, Wu C, Liu P, Wang J, Coombes KR (2005) Applications of beta-mixture
models in bioinformatics. Bioinformatics 21: 2118–2122.
50. Fraley F, Raftery A (2002) Model-based clustering, discriminant analysis, and
density estimation. J Am Stat Assoc 97: 611–631.
51. Houseman EA, Coull BA, Betensky RA (2006) Feature-specific penalized latent
class analysis for genomic data. Biometrics 62: 1062–1070.
52. Cashen AF, Shah AK, Todt L, Fisher N, DiPersio J (2008) Pharmacokinetics of
decitabine administered as a 3-h infusion to patients with acute myeloid
leukemia (AML) or myelodysplastic syndrome (MDS). Cancer Chemother
Pharmacol 61: 759–766.
53. Pfaffl MW (2001) A new mathematical model for relative quantification in real-
time RT-PCR. Nucleic Acids Res 29: e45.
Bladder Cancer Epigenetics
PLoS ONE | www.plosone.org 10 August 2010 | Volume 5 | Issue 8 | e12334